News and Trends 15 Sep 2022 New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 Tridek-One brings in €16M to develop auto-immune diseases candidates Tridek-One SAS, a French biotech startup specialized in the research and development of CD31 agonists to restore immune balance, has closed a €16 million ($16.1 million) new financing round. The financing was led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures, as well as historical investors AdBio partners and […] September 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 New company formed to boost life sciences in Singapore ClavystBio, a company established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek, has launched, with its mission to accelerate the commercialization of life sciences discoveries and innovation in Singapore. The life sciences sector is set to be a key driver of Singapore’s future economy. The sector currently employs 25,000 workers and contributes to […] September 15, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Recursion adds FAP and C. diff clinical trials Recursion Pharmaceuticals has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. The phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule […] September 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 NTU Singapore opens microbiome research center to study obesity and chronic diseases Nanyang Technological University, Singapore (NTU Singapore) has created the Centre for Microbiome Medicine – a research facility that aims to improve human health and find new ways to treat diseases by leveraging the microbiome, which are naturally present microorganisms that play a vital role in our wellbeing. The research centre at NTU Singapore’s Lee Kong […] September 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Pancreatic cancer study using dual-cell therapy yields positive results Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Sep 2022 Rivaling the Golden Triangle at Bristol’s Science Creates hub The Golden Triangle region hosts much of the U.K.’s biotech innovation. However, there are many hubs emerging across the nation, with Bristol’s Science Creates network being one thriving example. The U.K. hosts one of Europe’s leading biotech industries in terms of startup formation, scientific publications and investments. “The U.K. punches well above its weight with […] September 14, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […] September 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 SparingVision raises €75M for genomic medicines for ocular diseases SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […] September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email